NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Kiniksa Pharmaceuticals International, plc (KNSA) Stock Analysis

Kiniksa Pharmaceuticals International, plc (KNSA) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KNSA

$79.70

−$3.47 (−4.17%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KNSA with… →

KNSA Key Statistics

As of Oct 21, 2026
Trading
Open
$84.06
Previous Close
$83.17
Day's Range
78.74–84.06
52-Week Range
35.20–84.06
Volume
838.13K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.04
Valuation
Market Cap
$6.22B
P/E Ratio
80.51
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
49.27
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.40
EPS (ttm)Profit attributable to each share over the last twelve months.
0.99
Financials (FY)
Revenue (FY)
$677.56M+60.09%
Net Income (FY)
$59.01M
Profit marginThe share of revenue left as profit after all costs and taxes.
9.59%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.29M
1-Year Return
+105.15%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
599.01K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, KNSA closed at $79.70, +105.15% over 1 year.

Kiniksa Pharmaceuticals International, plc (KNSA) has a market capitalization of $6.22B.

In fiscal 2025, KNSA reported revenue of $677.56M.

KNSA Stock Return by Calendar Year

Kiniksa Pharmaceuticals International, plc (KNSA) return since May 2018: what $10,000 became

1 year
$10,000 $20,515
+105.15%
5 years
$10,000 $72,719
+627.19%
Since May 2018
$10,000 $41,061
+310.61%

If you had invested $10,000 in Kiniksa Pharmaceuticals International, plc (KNSA) at the close on May 25, 2018, the earliest close on record here, it would have been worth $41,061 at the close on October 21, 2026: +310.61% in total, +18.29% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+93.21%
2025+108.54%
2024+12.77%
2023+17.09%
2022+27.27%
2021−33.39%
2020+59.76%
2019−60.63%
2018 (partial year)+44.72%

As of October 21, 2026.

KNSA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$677.56M$59.01M8.7%
2024$423.24M−$43.19M−10.2%
2023$270.26M$14.08M5.2%
2022$220.18M$183.36M83.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$677.56M$370.35M$77.22M$59.01M8.7%
2024$423.24M$362.33M−$45.62M−$43.19M−10.2%
2023$270.26M$236.85M−$25.20M$14.08M5.2%
2022$220.18M$197.29M$9.77M$183.36M83.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KNSA Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricKNSADrug Manufacturers - Specialty & Generic medianvs median
P/E80.5120.314.0x the median
P/S ratio7.402.103.5x the median
Profit margin9.59%−8.14%17.7 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Kiniksa Pharmaceuticals International, plc (KNSA) at $6.22B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 366 employees.

The most recent close on file for KNSA is $79.70, dated October 21, 2026. That is −$3.47 (−4.17%) against the previous close. Over the past 52 weeks the price has ranged from $35.20 to $84.06. The latest close sits 126.42% above that 52-week low.

Financial Health

In fiscal 2025, Kiniksa Pharmaceuticals International, plc reported revenue of $677.56M. That is +60.09% against the prior fiscal year, when revenue was $423.24M. The same year closed with net income of $59.01M. Profit margin runs at 9.59%. That is 17.7 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are 0.99.

Across the 4 fiscal years on file, revenue moves from $220.18M in 2022 to $677.56M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 80.51 times earnings. That is 4 times the Drug Manufacturers - Specialty & Generic median of 20.31. On forward earnings the ratio is 49.27. The price-to-sales ratio is 7.4. On price-to-sales that is 3.5 times the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +105.15%. Measured over 5 years, that is +48.71% a year compounded. The reported beta is 0.04. Annualized volatility over the trailing 8 years is 63.09%.

Growth & Income

The record shows no dividend for KNSA.

The strongest complete calendar year on file is 2025 at +108.54%; the weakest is 2019 at −60.63%. Of the 7 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is +93.21% year to date.

Peer Comparison

Kiniksa Pharmaceuticals International, plc (KNSA) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kiniksa Pharmaceuticals International, plc KNSA $6.22B 80.5
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Kiniksa Pharmaceuticals International, plc trades at a P/E of 80.5.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Visit website →